ABVX Abivax SA

DGAP-News: Abivax 2021 Financial Communication Calendar

DGAP-News: ABIVAX / Key word(s): Miscellaneous
Abivax 2021 Financial Communication Calendar

03.12.2020 / 18:00
The issuer is solely responsible for the content of this announcement.


Abivax 2021 Financial Communication Calendar


PARIS, FRANCE, December 3, 2020 - 6:00 p.m. (CET) - Abivax (Euronext Paris: FR0012333284 - ABVX), a clinical-stage biotechnology company harnessing the immune system to develop novel treatments for inflammatory diseases, viral diseases and cancer, today publishes its 2021 financial communication calendar.

  • Thursday, April 1, 2021
    Publication of financial statements as of December 31, 2020
     
  • Friday, April 30, 2021
    Publication and release of the 2020 annual financial report
     
  • Friday, June 4, 2021 - 10.00 a.m.
    Shareholders meeting
     
  • Thursday, September 23, 2021
    Publication of financial statements as of June 30, 2021
     
  • Thursday, September 30, 2021
    Publication and release of 2021 half year report


About Abivax ()
Abivax, a clinical stage biotechnology company, is mobilizing the body's natural immune machinery to treat patients with chronic inflammatory diseases, viral infections, and cancer. Abivax is listed on Euronext compartment C (ISIN: FR0012333284 - Mnémo: ABVX). Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma. More information on the company is available at . Follow us on Twitter @ABIVAX_.


Contacts

Abivax
Communications
Regina Jehle

63
Investors
LifeSci Advisors
Chris Maggos

Press Relations & Investors Europe
MC Services AG
Anne Hennecke

22
Public Relations France
Actifin
Ghislaine Gasparetto

24
Public Relations France
DGM Conseil
Thomas Roborel de Climens

84
Public Relations USA
Rooney Partners LLC
Marion Janic



03.12.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at


1152398  03.12.2020 

fncls.ssp?fn=show_t_gif&application_id=1152398&application_name=news&site_id=research_pool
EN
03/12/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Abivax SA

Abivax: 1 director

A director at Abivax sold after exercising options/sold 1,104,640 shares at 54.000EUR and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over t...

Martial Descoutures
  • Martial Descoutures

Abivax : A well-deserved success, Outperform confirmed

We are significantly raising our TP from € 24 to € 88 following the positive results of the phase 3 induction trial (ABTECT) for obefazimod in ulcerative colitis. Obefazimod achieved significant clinical remission rates higher than those observed in phase 2b, and comparable to the best agents under development. Based on these results, we believe that Abivax is a credible M&A target for a pharma player looking to strengthen its position in immunology. Outperform rating reiterated.

Martial Descoutures
  • Martial Descoutures

Abivax : Un succès bien mérité, Surperformance confirmée

Nous relevons significativement notre OC de 24 € à 88 € suite aux résultats positifs de la phase 3 (ABTECT) en induction d’obefazimod dans la rectocolite hémorragique. Obefazimod a atteint des taux de rémission clinique significatifs supérieurs à ceux observés en phase 2b, et comparables aux meilleurs agents en développement. Suite à ces résultats, nous croyons qu’Abivax est une cible crédible d’acquisition pour une Pharma voulant se renforcer en Immunologie. Recommandation Surperformance réitér...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch